Intuitive Surgical, Inc.

- There is no explicit mention of any current or planned new fundraising through debt or equity on page 5. - The company has significant cash and investments ($8.3 billion as of Q3) and discusses expected declines in interest yields, but no plans for raising capital are indicated. - Capital expenditures are planned between $1 billion and $1.2 billion primarily for facility construction, but funding sources are not detailed as new fundraising. - The discussion touches on revenue growth, margin improvements, and operational expenses but does not include intentions to raise new equity or debt. - Overall, there is no evidence from the provided pages that the company is planning new debt or equity fundraising in the near term.

- Capital expenditures are expected to be in the range of $1 billion to $1.2 billion, primarily for planned facility construction activities (Page 3). - There is ongoing investment in the high-volume INA manufacturing facility in Mexicali to support production growth (Page 3). - Progressive trade-ins of da Vinci 5 systems over multiple years will lead to refurbishment opportunities, with potential segmentation by site of care and geography (Page 4). - Broad launch of da Vinci 5 planned by mid-2025, with continued hardware and software innovation investments (Page 5). - Investment in digital infrastructure with the expansion of Hub platform and move toward cloud implementations to enhance data tracking and workflow integration (Page 5).

- Procedure growth is expected to be within 16% to 17% for full year 2024, slightly raised from prior forecasts (Page 3). - U.S. multiport system procedures have a five-year CAGR of 17%, with global installed base growth and broadening system usage (Page 1). - Ion procedures have an extraordinary five-year CAGR of 205%, with ongoing system and software innovation and expansion into new indications and geographies (Page 1). - Continued growth in international markets, including Japan, Germany, France, and the U.K., though Europe and China face capital pressure and market challenges (Pages 3 and 5). - Introduction and ramp of da Vinci 5 systems projected, with 110 placed in Q3 and broad launch expected by mid-2025, with anticipated modest quarter-over-quarter supply increases (Pages 3 and 5). - Expanding into new procedure types (appendectomy, foregut, HPB) and sites of care, with penetration deepening in existing indications and launching in emerging markets (Pages 5 and 3). - Usage-based capital arrangements and refurbished system sales expected to grow cautiously over multiple years (Page 4).

- Procedure growth for full year 2024 is expected within 16% to 17%, raised from previous 15.5%-16% range. - Gross profit margin anticipated to be between 68.5% and 69% of net revenue in 2024. - Operating expense growth lowered slightly to a range of 10% to 12% for 2024. - Non-cash stock compensation expense forecasted between $670 million and $690 million in 2024. - Other income, primarily interest income, expected between $325 million and $345 million in 2024. - Capital expenditures projected at $1 billion to $1.2 billion mainly for facility construction. - Effective tax rate expected between 22% to 23% of pre-tax income for 2024. - Pro forma operating margin projected around mid-30% range with no management objective above 40%. - Gross margins may be slightly lower in 2025 due to incremental depreciation expenses from new product ramp-up. - Earnings per share (EPS) for Q3 2024 was $1.84 (pro forma), up 25% year-to-date from prior year.

- No specific figures on current or expected order book or pending orders were provided in the transcript. - There are strong capital placements with 379 systems placed in Q3 2024 versus 312 in Q3 2023. - U.S. system placements increased to 219 in Q3 2024 from 159 the previous year, including 110 da Vinci 5 systems. - Outside the U.S., 160 systems were placed in Q3 2024 compared to 153 last year. - Leasing arrangements are popular and make up 58% of Q3 placements, indicating ongoing demand. - Discussion of progressive trade-ins and refurbishments suggests a multi-year cycle of system upgrades. - Demand appears stable in the U.S. but there are continued capital pressures in Europe and broad stress in China’s healthcare market. - Dual console availability is expected to increase next year, potentially impacting order flow positively.